Buy Persistent Systems Ltd for the Target Rs 6,200 by Motilal Oswal Financial Services Ltd
Takeaways from our meeting with the CFO Core growth intact; AI/license monetization real but evolving; Europe M&A likely
* We met with the CFO of Persistent Systems (PSYS), Mr. Vinit Teredesai, and the leadership team. Key points from our meeting:
1) We expect BFSI to be the strongest vertical and could lead growth in FY27E, followed by healthcare and hitech, although SaaS remains relatively softer
2) AI and license revenue, coupled with Sasva and iAura, continue to provide PSYS with a competitive edge over the market for now
3) Margins are expected to operate within a narrow range
4) M&A strategy is likely to focus on Europe and diversification.
* Despite turbulences, we expect PSYS to achieve its USD2b run rate target by 4QFY27E, and believe the core growth thesis remains intact. We value PSYS at 34x FY28E EPS. Reiterate BUY with a TP of INR6,200.
BFSI to lead in FY27E, followed by Healthcare and Hi-Tech
* BFSI remains the strongest vertical and is expected to lead growth in FY27E, driven by new logo additions and increased wallet share from large, systemically important banks (refer to Exhibit 5).
* Wealth management, brokerage, and insurance are broadening the client base within the vertical. Healthcare remains structurally supportive, although client-specific issues could result in some short-term turbulence, with growth from other healthcare clients partially offsetting the impact.
* Hi-tech is bifurcated: CMT and select enterprise clients are doing well, while hardware SaaS and PE-backed tech remain soft, in line with macros and AI impact.
Valuation and view
* We believe the core growth thesis remains intact, supported by continued BFSI momentum, differentiated AI and platform-led offerings, and a disciplined M&A strategy aimed at expanding its European presence and reducing geographic concentration.
* While AI/license revenues may remain volatile on a quarterly basis, they continue to strengthen PSYS’s positioning in large enterprise transformation programs.
* We model ~16% USD revenue CAGR over FY26-28E, supported by a combination of organic growth and selective acquisitions. Along with gradual margin expansion, this translates into ~20-22% EPS CAGR, still among the stronger growth profiles in mid-tier IT. We continue to value PSYS at 34x FY28E EPS and reiterate BUY with a TP of INR 6,200.
Margins: Disciplined band, growth is the priority
* PSYS has guided for margins in the 16-17% operating band and considers the target achieved. Management’s posture is clear: growth reinvestment takes precedence beyond 17%.
* Productivity metrics — revenue per employee and cost per employee in USD terms — are the preferred health indicators over headcount alone. At ~USD1.8b annualized revenue with the USD2b milestone in reach, we see limited margin contraction risk; the band is conservative enough to absorb reinvestment without a structural reset.
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
